Transient loss of vision is associated with an increased risk for cardiovascular events within 14 days of diagnosis, and risks may persist for up to 10 years, a study finds. Medscape Medical News
Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food an…
Uncategorized
Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote “FOR” Alcon Merger
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that leading independent proxy…
Uncategorized
Voretigene neparvovec shows light sensitivity improvement
PARIS — A 5-year interim analysis of the PERCEIVE real-world study showed sustained improvement of light sensitivity in patients treated with voretigene neparvovec.“This is the biggest real-world analysis of voretigene neparvovec,” Dominik Fischer, MD,…
Uncategorized
HALT Max technology boosts effect of Essilor Stellest 2.0 lenses
Essilor Stellest 2.0 lenses with HALT Max technology led to significantly slower axial elongation than standard Essilor Stellest lenses, according to a study published in Translational Vision Science & Technology.Essilor Stellest lenses slow myopia pro…
Uncategorized
Organic chemistry returns
That’s right — organic chemistry.You thought you were done with orgo. Admit it, the first thing you did after reading the headline of this column was sprint to your safe spot. You were so traumatized by the mere mention of organic chemistry that you pu…